Objective:To systematically evaluate the endometrial thickening and Chinese herbal medicine intervention effects during endocrine therapy following breast cancer surgery.Methods:Computerized searches were performed on...Objective:To systematically evaluate the endometrial thickening and Chinese herbal medicine intervention effects during endocrine therapy following breast cancer surgery.Methods:Computerized searches were performed on CNKI,CBM,Wanfang,VIP,Pub Med,Embase,and Cochrane to gather randomized controlled trials(RCTs)of endometrial thickening combined with Chinese herbal medicine intervention during endocrine therapy after breast cancer surgery.The meta analysis is done using Rev Man 5.4,and the retrieval range is from the database's creation to January 2023.Results:There were 710 patients enrolled in a total of 12 RCTs.The results of Meta-analysis were as follows:combined with Chinese herbal medicine treatment for 3 months of endometrial thickness(MD=-1.12,95%CI[-1.47,0.77],P<0.00001);6 months endometrial thickness(MD=-1.90,95%CI[-2.38,-1.42],P<0.00001);endometrial thickness at 12 months(MD=-2.24,95%CI[-2.96,-1.52],P<0.00001);modified Kupperman score(MD=-10.45,95%CI[-19.10,-1.80],P=0.02);TCM syndrome score(SMD=-1.53,95%CI[-1.84,-1.22],P<0.00001);KPS score(MD=3.75,95%CI[2.81,4.68],P<0.00001);there was no significant difference in CA153,CEA,FSH and E2 between the two groups.Conclusion:After breast cancer surgery,endocrine therapy combined with Chinese herbal medicine can significantly lessen endometrial thickening and enhance patient quality of life.展开更多
Objective：To evaluate the effect of Chinese herbs decoction Shu-Gan-Liang-Xue on endocrine therapy-associated hot flashes symptom in breast cancer patients.Methods：Sixty-six patients with breast cancer receiving adj...Objective：To evaluate the effect of Chinese herbs decoction Shu-Gan-Liang-Xue on endocrine therapy-associated hot flashes symptom in breast cancer patients.Methods：Sixty-six patients with breast cancer receiving adjuvant endocrine therapy were categorized to two groups,the control group received endocrine therapy alone,the other group is administered with Chinese herbs decoction Shu-Gan-Liang-Xue besides the endocrine therapy：Shu-Gan-Liang-Xue decoction was administered above 6 months per year for more than 2 years.Frequency of hot flashes per day was recorded,and the effect of Shu-Gan-Liang-Xue decoction on hot flashes symptom being assessed with Kupperman Scoring Index.Results：Sixty cases were analyzed,32 cases in endocrine therapy combining Chinese herbs decoction group,28 cases in mere endocrine therapy group.For hot flashes symptom,in Chinese herbs decoction administration group,7 cases（21.9%） reported symptom disappeared,22 cases（68.7%） reported symptom alleviated,3 cases（9.4%） reported symptom not changed;in endocrine therapy alone group,5 cases（17.9%） reported symptom disappeared,13 cases（46.4%） reported symptom alleviated,10 cases（10/28,35.7%） reported symptom not changed.The difference between two groups was statistically significant（P=0.013）.For sleeping disorder,in Chinese herbs decoction administration group,27 cases（84.4%） reported symptom improved,5 cases（15.6%） reported no change;in endocrine therapy alone group,16 cases（57.1%） symptom improved,12 cases（42.9%） reported no change in sleeping disorder（P=0.019）,the difference was also of significance statistically.Conclusion：Long-term Chinese herbs decoction administration remarkably improved hot flashes symptom and sleeping disorder associated with endocrine therapy,meanwhile without definite toxicity and influence on the risk of recurrence of tumor.展开更多
Background:Although de novo stage IV breast cancer is so far incurable,it has entered an era of individualized treatment and chronic disease management.Based on systemic treatment,whether the surgical resection of pri...Background:Although de novo stage IV breast cancer is so far incurable,it has entered an era of individualized treatment and chronic disease management.Based on systemic treatment,whether the surgical resection of primary or metastatic foci of de novo stage IV breast cancer can bring survival benefits is currently controversial.We aimed to explore the clinicopathological factors and current status of the management of de novo stage IV breast cancer in China to provide a reference for clinical decisions.Methods:Based on the assistance of Chinese Society of Breast Surgery,a retrospective study was conducted to analyze the clinical data of patients with de novo stage IV breast cancer in 33 centers from January 2017 to December 2018.The relationship between basic characteristic(age,menstrual status,family history,reproductive history,pathological type,estrogen receptor[ER]status,progesterone receptor[PR]status,human epidermal growth factor receptor 2[HER2]status,Ki-67 percentage,and molecular subtype),and metastasis sites(lung metastasis,liver metastasis,and bone metastasis)was examined by Pearson Chi-square tests.Results:A total of 468 patients with de novo stage IV breast cancer were enrolled.The median age of the enrolled patients was 51.5 years.The most common pathological type of primary lesion was invasive carcinoma(97.1%).Luminal A,luminal B,HER2 overexpressing,and triple-negative subtypes accounted for 14.3%,51.8%,22.1%,and 11.8% of all cases,respectively.Age,PR status,and HER2 status were correlated with lung metastasis(χ^(2)=6.576,4.117,and 8.643 and P=0.037,0.043,and 0.003,respectively).Pathological type,ER status,PR status,and molecular subtype were correlated with bone metastasis(χ^(2)=5.117,37.511,5.224,and 11.603 and P=0.024,<0.001,0.022,and 0.009,respectively).Age,PR status,HER2 status,Ki-67 percentage,and molecular subtype were correlated with liver metastasis(χ^(2)=11.153,13.378,10.692,21.206,and 17.684 and P=0.004,<0.001,0.001,<0.001,and 0.001,respectively).Combined treatment with paclitaxel and anthracycline was the most common first-line chemotherapy regimen for patients with de novo stage IV breast cancer(51.7%).Overall,91.5% of patients used paclitaxel-containing regimens.Moreover,59.3% of hormone receptor-positive patients underwent endocrine therapy.Conclusions:In 2018,1.07% of patients from all studied centers were diagnosed with de novo stage IV breast cancer.This study indicated that 95.1% of patients received systemic therapy and 54.2% of patients underwent surgical removal of the primary lesion in China.展开更多
Objective：To observe the efficacy of Chinese medicine comprehensive therapeutic project in treating the middle/late stage primary hepatic carcinoma（PHC）.Methods：With prospective randomized controlled design, 97 pa...Objective：To observe the efficacy of Chinese medicine comprehensive therapeutic project in treating the middle/late stage primary hepatic carcinoma（PHC）.Methods：With prospective randomized controlled design, 97 patients with PHC were assigned to the test group（49 cases） treated with Chinese medicine comprehensive therapy using Oleum fructus bruceas intervention combining oral intake of Ganji Decoction（肝积方） and external application of Ailitong（癌理通）,and the control group（48 cases） treated with chemotherapeutic agents combining iodized oil chemo-embolization and analgesics.The immediate and long-term efficacy,adverse reaction,pain-relieving initial time（PRIT） and pain-relieving sustained time（PRST） of the treatment,as well as the change in patients＇ quality of life（QOL） were observed.Results：The difference between the two groups in illness control rate was statistically insignificant（P〉0.05）,but the adverse reaction occurence rate in the test group was lesser than that in the control group（P〈0.05）.PRIT was insignificantly different in the two groups（P〉0.05）,but the PRST was significantly superior in the test group than that in the control group（10.37±2.18 h vs 7.78±1.95 h,P〈0.01）.After treatment,the increased Karnofsky scores in the test group indicated that the patients＇ somatic activity,symptoms and QOL were improved significantly,which were significantly superior to those in the control group（P〈0.05）.The survival rate in the two groups was similar at the 3rd month after treatment,but the test group did show superiority in terms of half- and 1-year survival rate（65.9%vs 42.5%and 38.6%vs 18.1%,respectively,P〈0.05）.The median survival time in the test group was 8.9 months and that in the control group was 5.3 months.Conclusion：Chinese medicine comprehensive therapy is an effective treatment for the middle/late stage patients of PHC,and it could extend the PRST,improve the patients＇ QOL and long-term survival with less adverse reaction.展开更多
基金State Administration of Traditional Chinese Medicine(No.ZyzB-2022-798)National Natural Science Foundation of China(No.82205222)Special Research Project of Beijing Municipal Health Commission on Capital Health Development(No.First edition 2022-4-2234)。
文摘Objective:To systematically evaluate the endometrial thickening and Chinese herbal medicine intervention effects during endocrine therapy following breast cancer surgery.Methods:Computerized searches were performed on CNKI,CBM,Wanfang,VIP,Pub Med,Embase,and Cochrane to gather randomized controlled trials(RCTs)of endometrial thickening combined with Chinese herbal medicine intervention during endocrine therapy after breast cancer surgery.The meta analysis is done using Rev Man 5.4,and the retrieval range is from the database's creation to January 2023.Results:There were 710 patients enrolled in a total of 12 RCTs.The results of Meta-analysis were as follows:combined with Chinese herbal medicine treatment for 3 months of endometrial thickness(MD=-1.12,95%CI[-1.47,0.77],P<0.00001);6 months endometrial thickness(MD=-1.90,95%CI[-2.38,-1.42],P<0.00001);endometrial thickness at 12 months(MD=-2.24,95%CI[-2.96,-1.52],P<0.00001);modified Kupperman score(MD=-10.45,95%CI[-19.10,-1.80],P=0.02);TCM syndrome score(SMD=-1.53,95%CI[-1.84,-1.22],P<0.00001);KPS score(MD=3.75,95%CI[2.81,4.68],P<0.00001);there was no significant difference in CA153,CEA,FSH and E2 between the two groups.Conclusion:After breast cancer surgery,endocrine therapy combined with Chinese herbal medicine can significantly lessen endometrial thickening and enhance patient quality of life.
文摘Objective：To evaluate the effect of Chinese herbs decoction Shu-Gan-Liang-Xue on endocrine therapy-associated hot flashes symptom in breast cancer patients.Methods：Sixty-six patients with breast cancer receiving adjuvant endocrine therapy were categorized to two groups,the control group received endocrine therapy alone,the other group is administered with Chinese herbs decoction Shu-Gan-Liang-Xue besides the endocrine therapy：Shu-Gan-Liang-Xue decoction was administered above 6 months per year for more than 2 years.Frequency of hot flashes per day was recorded,and the effect of Shu-Gan-Liang-Xue decoction on hot flashes symptom being assessed with Kupperman Scoring Index.Results：Sixty cases were analyzed,32 cases in endocrine therapy combining Chinese herbs decoction group,28 cases in mere endocrine therapy group.For hot flashes symptom,in Chinese herbs decoction administration group,7 cases（21.9%） reported symptom disappeared,22 cases（68.7%） reported symptom alleviated,3 cases（9.4%） reported symptom not changed;in endocrine therapy alone group,5 cases（17.9%） reported symptom disappeared,13 cases（46.4%） reported symptom alleviated,10 cases（10/28,35.7%） reported symptom not changed.The difference between two groups was statistically significant（P=0.013）.For sleeping disorder,in Chinese herbs decoction administration group,27 cases（84.4%） reported symptom improved,5 cases（15.6%） reported no change;in endocrine therapy alone group,16 cases（57.1%） symptom improved,12 cases（42.9%） reported no change in sleeping disorder（P=0.019）,the difference was also of significance statistically.Conclusion：Long-term Chinese herbs decoction administration remarkably improved hot flashes symptom and sleeping disorder associated with endocrine therapy,meanwhile without definite toxicity and influence on the risk of recurrence of tumor.
文摘Background:Although de novo stage IV breast cancer is so far incurable,it has entered an era of individualized treatment and chronic disease management.Based on systemic treatment,whether the surgical resection of primary or metastatic foci of de novo stage IV breast cancer can bring survival benefits is currently controversial.We aimed to explore the clinicopathological factors and current status of the management of de novo stage IV breast cancer in China to provide a reference for clinical decisions.Methods:Based on the assistance of Chinese Society of Breast Surgery,a retrospective study was conducted to analyze the clinical data of patients with de novo stage IV breast cancer in 33 centers from January 2017 to December 2018.The relationship between basic characteristic(age,menstrual status,family history,reproductive history,pathological type,estrogen receptor[ER]status,progesterone receptor[PR]status,human epidermal growth factor receptor 2[HER2]status,Ki-67 percentage,and molecular subtype),and metastasis sites(lung metastasis,liver metastasis,and bone metastasis)was examined by Pearson Chi-square tests.Results:A total of 468 patients with de novo stage IV breast cancer were enrolled.The median age of the enrolled patients was 51.5 years.The most common pathological type of primary lesion was invasive carcinoma(97.1%).Luminal A,luminal B,HER2 overexpressing,and triple-negative subtypes accounted for 14.3%,51.8%,22.1%,and 11.8% of all cases,respectively.Age,PR status,and HER2 status were correlated with lung metastasis(χ^(2)=6.576,4.117,and 8.643 and P=0.037,0.043,and 0.003,respectively).Pathological type,ER status,PR status,and molecular subtype were correlated with bone metastasis(χ^(2)=5.117,37.511,5.224,and 11.603 and P=0.024,<0.001,0.022,and 0.009,respectively).Age,PR status,HER2 status,Ki-67 percentage,and molecular subtype were correlated with liver metastasis(χ^(2)=11.153,13.378,10.692,21.206,and 17.684 and P=0.004,<0.001,0.001,<0.001,and 0.001,respectively).Combined treatment with paclitaxel and anthracycline was the most common first-line chemotherapy regimen for patients with de novo stage IV breast cancer(51.7%).Overall,91.5% of patients used paclitaxel-containing regimens.Moreover,59.3% of hormone receptor-positive patients underwent endocrine therapy.Conclusions:In 2018,1.07% of patients from all studied centers were diagnosed with de novo stage IV breast cancer.This study indicated that 95.1% of patients received systemic therapy and 54.2% of patients underwent surgical removal of the primary lesion in China.
基金Supported by Guangdong Administration of Sciences and Technology(No.2005B36001012)
文摘Objective：To observe the efficacy of Chinese medicine comprehensive therapeutic project in treating the middle/late stage primary hepatic carcinoma（PHC）.Methods：With prospective randomized controlled design, 97 patients with PHC were assigned to the test group（49 cases） treated with Chinese medicine comprehensive therapy using Oleum fructus bruceas intervention combining oral intake of Ganji Decoction（肝积方） and external application of Ailitong（癌理通）,and the control group（48 cases） treated with chemotherapeutic agents combining iodized oil chemo-embolization and analgesics.The immediate and long-term efficacy,adverse reaction,pain-relieving initial time（PRIT） and pain-relieving sustained time（PRST） of the treatment,as well as the change in patients＇ quality of life（QOL） were observed.Results：The difference between the two groups in illness control rate was statistically insignificant（P〉0.05）,but the adverse reaction occurence rate in the test group was lesser than that in the control group（P〈0.05）.PRIT was insignificantly different in the two groups（P〉0.05）,but the PRST was significantly superior in the test group than that in the control group（10.37±2.18 h vs 7.78±1.95 h,P〈0.01）.After treatment,the increased Karnofsky scores in the test group indicated that the patients＇ somatic activity,symptoms and QOL were improved significantly,which were significantly superior to those in the control group（P〈0.05）.The survival rate in the two groups was similar at the 3rd month after treatment,but the test group did show superiority in terms of half- and 1-year survival rate（65.9%vs 42.5%and 38.6%vs 18.1%,respectively,P〈0.05）.The median survival time in the test group was 8.9 months and that in the control group was 5.3 months.Conclusion：Chinese medicine comprehensive therapy is an effective treatment for the middle/late stage patients of PHC,and it could extend the PRST,improve the patients＇ QOL and long-term survival with less adverse reaction.
